# Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

> **NCT07538583** · PHASE2,PHASE3 · RECRUITING · sponsor: **Quoin Pharmaceuticals** · enrollment: 16 (estimated)

## Conditions studied

- Netherton Syndrome

## Interventions

- **DRUG:** QRX003

## Key facts

- **NCT ID:** NCT07538583
- **Lead sponsor:** Quoin Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07538583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07538583, "Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07538583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*